CULLINAN THERAPEUTICS, INC.
Moat Score — Cullinan Therapeutics, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Cullinan holds patents around its proprietary bispecific T cell engager platform and in-licensed assets like velinotamig, plus FDA Fast Track designation for CLN-049, but none of its wholly-owned candidates are yet approved, so intangible value remains largely prospective. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage company with no marketed product and no manufacturing scale, Cullinan has no cost advantage versus larger, better-capitalized biopharma competitors like Amgen or Roche. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Specialty biologics for autoimmune disease and oncology can command premium pricing once approved, and zipalertinib's NDA submission with Taiho is a step toward that, but with nothing yet approved Cullinan has no realized pricing power today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Drug development and prescribing carry no network effect; Cullinan's therapies do not become more valuable to one patient or physician because more patients or physicians use them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a physician and patient commit to a treatment protocol there is some inertia, and Fast Track/orphan-type designations can entrench first movers, but with no approved Cullinan products today there is no realized switching-cost moat yet. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The T cell engager and targeted-oncology space named in Cullinan's own 10-K includes Amgen, Roche, AstraZeneca, Merck, Novartis, GSK, and Xencor, a crowded field of well-funded competitors that leaves no efficient-scale barrier protecting Cullinan's position. |